Fig. 6

Gefitinib treatment inhibits intra-tibial tumor growth when administered subsequent to tumor formation. a Diagram showing the experimental scheme, where PC-3 M-luc2 cells were implanted at day 0. Luciferase imaging was performed at days 15, 23, 29 and 40. Gefetinib (200 mg/kg body weight) or placebo containing 0.5 % Tween 20 administration through gavage started at day 15. X-rays were taken at day 40. b In vivo luciferase images were taken at 40 days for both groups, followed by a representative x-ray picture of a set of animals in both groups. c Quantitation of in vivo luciferase data from N = 6 animals in both control and Gefinitib treated animals, starting from 15 days till the end of the experiment on the 40th day. Wilcoxon rank sum test were performed between control and experimental groups, where * represents p < 0.05